International: +1-347-960-6455
Achondroplasia Therapeutics - Pipeline Analysis 2018

Achondroplasia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10153 Published: January 2019 Pages: 74 Available format: 
Therapeutic Area(s): Others Report Type: Indication Pipeline Reports
Select License Type
$1500
$1800
$2700
Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Signs and Symptoms

4.3 Causes

4.4 Diagnosis

4.5 Treatment

4.6 Epidemiology

4.7 Key Drivers

4.7.1 Technological Advancements in Drug Development

4.7.2 Positive Clinical Results

4.8 Key Barriers

4.8.1 Increasing Healthcare Cost

4.9 Achondroplasia Therapeutics Pipeline Analysis

4.9.1 Pipeline Analysis by Phase

4.9.2 Pipeline Analysis by Molecule Type

4.9.3 Pipeline Analysis by Route of Administration

4.9.4 Pipeline Analysis by Company

Chapter 5. Achondroplasia Therapeutics Pipeline Analysis by Phase (2018) 24

5.1 Phase III

5.1.1 Vosoritide

5.1.1.1 Clinical trials

5.1.1.2 Clinical trial results

5.1.1.3 Strategic development

5.2 Phase I

5.2.1 TransCon CNP

5.2.1.1 Pre-Clinical studies

5.2.1.2 Clinical trials

5.2.1.3 Strategic development

5.2.1.4 Technology

5.2.2 XXXX

5.2.2.1 Pre-Clinical studies

5.2.2.2 Strategic development

5.2.2.3 Designation

5.3 Pre-Clinical

5.3.1 RBM 007

5.3.1.1 Strategic development

5.3.1.2 Technology

5.3.1.3 Patent

5.3.2 XXXX

5.3.3 XXXX

5.3.3.1 Pre-Clinical studies

5.3.3.2 Strategic development

5.3.3.3 Grant

5.4 Discovery

5.4.1 XXXX

5.5 Discontinued

5.5.1 XXXX

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking

7.2 Patents for Achondroplasia

7.3 SWOT Analysis

7.3.1 Strengths

7.3.2 Weaknesses

7.3.3 Opportunities

7.3.4 Threats

Chapter 8. Company Profiles

8.1 Ascendis Pharma A/S

8.1.1 Business Overview

8.1.2 Product and Service Offerings

8.2 RIBOMIC Inc.

8.2.1 Business Overview

8.2.2 Product and Service Offerings

8.3 XXXX

8.3.1 Business Overview

8.3.2 Product and Service Offerings

8.4 XXXX

8.4.1 Business Overview

8.4.2 Product and Service Offerings

8.5 XXXX

8.5.1 Business Overview

8.5.2 Product and Service Offerings

8.6 XXXX

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 BioMarin Pharmaceutical Inc.

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 XXXX

8.8.1 Business Overview

8.8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

 

TABLE 1 PIPELINE ANALYSIS OF ACHONDROPLASIA THERAPEUTICS, BY COMPANY (2018)

TABLE 2 DESCRIPTION OF VOSORITIDE

TABLE 3 CLINICAL TRIALS OF VOSORITIDE

TABLE 4 PHASE II TRIAL DISPOSITION AND DEMOGRAPHICS

TABLE 5 CLINICAL RESULTS OF VOSORITIDE

TABLE 6 DESCRIPTION OF TRANSCON CNP

TABLE 7 CLINICAL TRIALS OF TRANSCON CNP

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 DESCRIPTION OF XXXX

TABLE 10 DESCRIPTION OF XXXX

TABLE 11 DESCRIPTION OF XXXX

TABLE 12 DESCRIPTION OF XXXX

TABLE 13 DESCRIPTION OF XXXX

TABLE 14 DESCRIPTION OF XXXX

TABLE 15 ASCENDIS PHARMA A/S – AT A GLANCE

TABLE 16 RIBOMIC INC. – AT A GLANCE

TABLE 17 XXXX – AT A GLANCE

TABLE 18 XXXX – AT A GLANCE

TABLE 19 XXXX – AT A GLANCE

TABLE 20 XXXX – AT A GLANCE

TABLE 21 BIOMARIN PHARMACEUTICAL INC. – AT A GLANCE

TABLE 22 XXXX – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH BY PRIMARY RESPONDANTS

FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 4 ACHONDROPLASIA THERAPEUTICS UNDER DEVELOPMENT (2018)

FIG 5 ACHONDROPLASIA THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6 ACHONDROPLASIA THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7 TRANSCON TECHNOLOGY

FIG 8 RIBOART SYSTEM

FIG 9 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 10 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 11 KEY PLAYERS BENCHMARKING

FIG 12 SWOT ANALYSIS